Researchers are proposing a bold new approach to cancer treatment: instead of waiting for tumors to relapse and develop resistance, doctors should switch therapies while the cancer is still vulnerable.
Kabul 24: Mathematical models suggest this proactive strategy could significantly limit the tumor’s ability to adapt and evolve, ultimately improving treatment outcomes.
In standard clinical practice, physicians typically continue with the first drug until it stops working and the cancer visibly returns. Only then do they move on to the next treatment. While this reactive method is common, it gives surviving cancer cells valuable time to mutate, grow stronger, and become resistant to future drugs.Scientists now recommend a more intelligent tactic: switch to the next therapy as soon as the tumor shrinks and weakens, before it has a chance to recover and build resistance. This is like preventing an opponent from catching their breath during a fight. Mathematical modeling shows that striking while the tumor is at its weakest dramatically increases the chances of defeating the cancer.
In some cases, using several drugs in rapid, well-timed succession could even eliminate larger tumors permanently.Dr. Robert Noble, senior lecturer in mathematics at City St George’s, University of London, who led the study, explains: “Although tumors often shrink initially under treatment, they frequently grow back.
These relapses are usually driven by a small number of cancer cells that have acquired mutations making them resistant to the therapy.”Mutations are random changes in a cell’s genetic instructions that occur during cell division.
If a mutation allows a cell to survive the current drug, that cell and its descendants can continue multiplying and eventually rebuild the tumor.Under the current standard approach, waiting for a visible relapse gives the remaining cancer cells more time to evolve. By the time doctors introduce the second treatment, some cells may already carry mutations that protect them against it as well.
The new findings suggest that smarter timing could turn cancer’s own evolutionary power against itself. By changing treatments before resistance fully emerges, doctors may prevent or delay relapse more effectively.
This proactive, evolution-aware strategy could become one of the key tools for making cancer therapies more successful and offer fresh hope to patients.
